• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    PRESIDENT, CHIEF COMMERCAL OFF Gallagher John E converted options into 42,486 shares and covered exercise/tax liability with 14,176 shares, increasing direct ownership by 155% to 46,528 units (SEC Form 4)

    4/3/25 4:36:31 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology
    Get the next $CERT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Gallagher John E

    (Last) (First) (Middle)
    C/O CERRTARA, INC.
    4 RADNOR CORPORATE CENTER, SUITE 350

    (Street)
    RADNOR PA 19087

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Certara, Inc. [ CERT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    PRESIDENT, CHIEF COMMERCAL OFF
    3. Date of Earliest Transaction (Month/Day/Year)
    04/01/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 04/01/2025 M 14,663 A $0(1) 32,881 D
    Common Stock 04/01/2025 F 4,646(2) D $9.9(1) 28,235 D
    Common Stock 04/01/2025 M 12,633 A $0(3) 40,868 D
    Common Stock 04/01/2025 F 4,327(2) D $9.9(3) 36,541 D
    Common Stock 04/01/2025 M 15,190 A $0(4) 51,731 D
    Common Stock 04/01/2025 F 5,203(2) D $9.9(4) 46,528 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (1) 04/01/2025 M 14,663 (1) 04/01/2025 Common Stock 14,663 $0 0 D
    Restricted Stock Units (3) 04/01/2025 M 12,633 (3) 04/01/2026 Common Stock 12,633 $0 12,633 D
    Restricted Stock Units (4) 04/01/2025 M 15,190 (4) 04/01/2027 Common Stock 15,190 $0 30,381 D
    Explanation of Responses:
    1. Each restricted stock unit ("RSU") was granted on April 1, 2023, under the Certara, Inc. ("Certara") 2020 Incentive Plan ("2020 Incentive Plan") and represents a right to receive one share of common stock or the cash equivalent. One-half of the RSUs vested and were settled on April 1, 2024. The remaining RSUs vested and settled on April 1, 2025.
    2. Represents shares of Certara withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") and PSUs described in footnotes 1, 3, and 4, exempt under Rule 16b-3.
    3. Each RSU was granted on April 1, 2023, under the 2020 Incentive Plan and represents a right to receive one share of common stock or the cash equivalent. One-third of the RSUs vested and were settled on April 1, 2024. One-third of the RSUs vested and were settled on April 1, 2025. The remaining one-third of the RSUs are scheduled to vest and settle on April 1, 2026.
    4. Each RSU was granted on April 1, 2024, under the 2020 Incentive Plan and represents a right to receive one share of common stock or the cash equivalent. One-third of the RSUs vested and were settled on April 1, 2025. The remaining two-thirds of the RSUs will vest and settle in equal parts on April 1, 2026 and April 1, 2027.
    /s/ Daniel Corcoran, Attorney-in-Fact for John E. Gallagher 04/03/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CERT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CERT

    DatePrice TargetRatingAnalyst
    5/8/2025$14.00Equal Weight → Overweight
    Barclays
    2/27/2025$16.00Buy
    TD Cowen
    9/27/2024$16.00Neutral → Buy
    UBS
    4/10/2024$23.00Sector Weight → Overweight
    KeyBanc Capital Markets
    4/4/2024Mkt Perform
    JMP Securities
    2/26/2024$19.00Market Perform
    Leerink Partners
    12/7/2023$17.00Neutral
    UBS
    12/5/2023Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $CERT
    Financials

    Live finance-specific insights

    See more
    • Certara Reports First Quarter 2025 Financial Results

      RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal year 2025. First Quarter Highlights: Revenue was $106.0 million, compared to $96.7 million in the first quarter of 2024, representing growth of 10%. Software revenue was $46.4 million, compared to $39.3 million in the first quarter of 2024, representing growth of 18%.Services revenue was $59.6 million, flat compared to $57.3 million in the first quarter of 2024, representing growth of 4%. Net income was $4.7 million, a $9.4 million increase compared to a net loss of $4.7 million in t

      5/5/25 4:15:00 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Certara Reports Preliminary First Quarter 2025 Financial Results; Announces $100 Million Share Repurchase Authorization

      Reiterates Full-Year 2025 GuidanceArsenal Capital Partners agrees to a one-year lock-up RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced expected revenue and bookings for the first quarter of 2025 based upon a preliminary review of first quarter results. Additionally, the company announced that its Board of Directors has authorized a stock repurchase program under which the company may repurchase up to $100 million of its outstanding common stock. "We are pleased with our first quarter performance, driven by strong commercial execution and demand for our software and services," said

      4/14/25 8:00:00 AM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Certara Reports Fourth Quarter 2024 Financial Results

      RADNOR, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the fourth quarter and full year 2024. Fourth Quarter Highlights: Revenue was $100.4 million, compared to $88.0 million in the fourth quarter of 2023, representing growth of 14%. Software revenue was $42.3 million, compared to $33.6 million in the fourth quarter of 2023, representing growth of 26%.Services revenue was $58.1 million, compared to $54.4 million in the fourth quarter of 2023, representing growth of 7%. Net income was $6.6 million, compared to a net loss of $12.5 million in the fourth quarter of 2023.Adjuste

      2/26/25 4:15:00 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology

    $CERT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT, PREDICTIVE TECH Aspbury Robert was granted 7,082 shares, covered exercise/tax liability with 15,846 shares and converted options into 26,626 shares, increasing direct ownership by 6% to 307,176 units (SEC Form 4)

      4 - Certara, Inc. (0001827090) (Issuer)

      4/3/25 4:44:38 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • PRESIDENT, CHIEF COMMERCAL OFF Pedersen Leif E was granted 7,082 shares, covered exercise/tax liability with 8,209 shares and converted options into 26,626 shares, increasing direct ownership by 26% to 125,203 units (SEC Form 4)

      4 - Certara, Inc. (0001827090) (Issuer)

      4/3/25 4:40:25 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • PRESIDENT, CHIEF COMMERCAL OFF Gallagher John E converted options into 42,486 shares and covered exercise/tax liability with 14,176 shares, increasing direct ownership by 155% to 46,528 units (SEC Form 4)

      4 - Certara, Inc. (0001827090) (Issuer)

      4/3/25 4:36:31 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology

    $CERT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Certara Inc.

      SC 13G - Certara, Inc. (0001827090) (Subject)

      11/14/24 8:38:56 AM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Amendment: SEC Form SC 13G/A filed by Certara Inc.

      SC 13G/A - Certara, Inc. (0001827090) (Subject)

      10/4/24 10:25:50 AM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G/A filed by Certara Inc. (Amendment)

      SC 13G/A - Certara, Inc. (0001827090) (Subject)

      2/13/24 5:01:03 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology

    $CERT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Certara upgraded by Barclays with a new price target

      Barclays upgraded Certara from Equal Weight to Overweight and set a new price target of $14.00

      5/8/25 8:23:49 AM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • TD Cowen initiated coverage on Certara with a new price target

      TD Cowen initiated coverage of Certara with a rating of Buy and set a new price target of $16.00

      2/27/25 6:17:48 AM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Certara upgraded by UBS with a new price target

      UBS upgraded Certara from Neutral to Buy and set a new price target of $16.00

      9/27/24 7:31:50 AM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology

    $CERT
    SEC Filings

    See more
    • SEC Form 10-Q filed by Certara Inc.

      10-Q - Certara, Inc. (0001827090) (Filer)

      5/5/25 4:31:57 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Certara Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Certara, Inc. (0001827090) (Filer)

      5/5/25 4:24:47 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Amendment: SEC Form SCHEDULE 13D/A filed by Certara Inc.

      SCHEDULE 13D/A - Certara, Inc. (0001827090) (Subject)

      4/14/25 5:15:03 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology

    $CERT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Certara Reports First Quarter 2025 Financial Results

      RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal year 2025. First Quarter Highlights: Revenue was $106.0 million, compared to $96.7 million in the first quarter of 2024, representing growth of 10%. Software revenue was $46.4 million, compared to $39.3 million in the first quarter of 2024, representing growth of 18%.Services revenue was $59.6 million, flat compared to $57.3 million in the first quarter of 2024, representing growth of 4%. Net income was $4.7 million, a $9.4 million increase compared to a net loss of $4.7 million in t

      5/5/25 4:15:00 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Certara to Participate in Upcoming Investor Conferences

      RADNOR, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: BofA Securities 2025 Healthcare ConferenceDate and Time: Tuesday, May 13 at 3:40 p.m. PT William Blair 45th Annual Growth Stock ConferenceDate and Time: Wednesday, June 4 at 12:40 p.m. CT Live webcasts for each of the conferences will be available on Certara's investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter. About CertaraCertara accelerates medicines using biosimulation software, technology, and

      4/29/25 4:15:00 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

      RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the launch of its Non-Animal Navigator™ solution designed to help biopharmaceutical companies lead the transition ignited by the FDA's Roadmap to Reducing Animal Testing in Preclinical Safety Studies. The Roadmap marks a pivotal moment in drug development. Companies that act now can future-proof their portfolios, gaining competitive advantage through faster timelines, lower costs, and stronger predictive evidence. Globally, there are thousands of monoclonal antibodies and antibody-drug conjugates (ADCs) currently in the preclinical phase of devel

      4/14/25 8:15:00 AM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology

    $CERT
    Leadership Updates

    Live Leadership Updates

    See more
    • Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions

      RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President of Drug Development Solutions, effective March 3rd, 2025. In this role, McKemey will lead Certara's global team of drug development scientists. Adrian joins Certara after serving as head of Enterprise Transformation at IQVIA and Senior Vice President and Head of the R&D Strategy Solutions at Quintiles. He has over 25 years of experience in research and development roles where he focused on business transformation, portfolio management and R&D strategies. Before IQVIA, he was a Principal with t

      3/5/25 4:15:00 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Certara Appoints John Reynders as New Independent Board Member

      RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. "We are excited to welcome an accomplished pharmaceutical industry leader with a track record of success to Certara's Board," said William F. Feehery, PhD, CEO of Certara. "John's expertise in artificial intelligence, data science, and life science will provide immense value. We will draw on that expertise as we continue to develop and integrate transformational software and services that accelerate new medicines and increase the productivity of pharma R&

      10/16/24 4:15:00 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • MaxCyte Appoints Cynthia Collins to its Board of Directors

      ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members. "I am pleased to welcome Cynthia to MaxCyte's Board of Directors," said Mahe

      10/15/24 8:05:00 AM ET
      $CERT
      $MXCT
      $PSTX
      Computer Software: Prepackaged Software
      Technology
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care